AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01049334
Drug: Flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
Trial: NCT02603224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control.
Trial: NCT01297348
Drug: 90ug levonorgestrel / 20 ug ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
Trial: NCT01297348
Drug: Oral Contraceptives containing 20 ug of ethinyl estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
Trial: NCT01628445
Drug: placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injected sc daily volume equal to active comparator
Trial: NCT01845831
Drug: Basal Bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
Trial: NCT02991404
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 0.125% bupivacaine
Trial: NCT01175616
Drug: Creatine
RxNorm normalized name: Creatine
DrugBank: Creatine (DB00148)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Creatine 5 grams daily.
Trial: NCT01845831
Drug: Glargine 50%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glargine will be prescribed at 50% of daily hospital dose.
Trial: NCT01845831
Drug: Glargine 80%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glargine will be prescribed at 80% of daily hospital dose.
Trial: NCT02229968
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02745990
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal salin is administered the same volume with rhEPO intravenously within 72h after birth, and every other day up to 32 weeks of corrected age..
Trial: NCT01585259
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline
Trial: NCT02188953
Drug: ACCS100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACCS100 is made from Hydrated Sodium Calcium Aluminosilicate, which is a substance generally recognized as safe by the U.S. FDA.
Trial: NCT01516970
Drug: NRTIs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The NRTIs (including tenofovir/emtricitabine \[Truvada\], lamivudine/zidovudine \[Combivir\]) will be administered as per the individual Summary of Product Characteristics (SmPCs) at the discretion of either the treating physician or Investigator.
Trial: NCT02188953
Drug: Calcium carbonate placebo
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01572116
Drug: Lidocaine with Epinephrine+ Normal saline
RxNorm normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDL injection of 0/4 ml of lidocaine %2 with epinephrine,and Normal saline
Trial: NCT01572116
Drug: Lidocaine with Epinephrine + sufentanil
RxNorm normalized name: epinephrine / lidocaine Cartridge [Xylocaine with Epinephrine]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PDL injection of 0/4 ml lidocaine with epinephrine and0/4 ml sufentanil ( 0/04 μg)
Trial: NCT03973515
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet
Trial: NCT02336958
Drug: pericarotidal infiltration (placebo comparator) saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
Trial: NCT00476736
Drug: Effect on small airways (N-Acetylcystein)
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00514514
Drug: Simulect®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4
Trial: NCT00760019
Drug: salsalate
RxNorm normalized name: Salsalate
DrugBank: Salsalate (DB01399)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1.5 grams orally 3 times daily
Trial: NCT00760019
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT02685462
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02685462
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02685462
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03537144
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV indomethacin will be given every 12 hours for 3 doses. If \<48 hours old, 1st dose 0.2 mg/kg, 2nd dose 0.1 mg/kg, and 3rd dose 0.1mg/kg. If 2-7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.2 mg/kg, and 3rd dose 0.2 mg/kg. If \>7 days old, 1st dose 0.2 mg/kg, 2nd dose 0.25 mg/kg, and 3rd dose 0.25 mg/kg.
Trial: NCT03537144
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15mg/kg/dose every 6 hours for 12 doses
Trial: NCT04092712
Drug: [14C]-CTP-543
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of radiolabeled CTP-543 (approximately 75 μCi) administered as an oral solution
Trial: NCT01281501
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 ml of 0.9% sodium chloride solution
Trial: NCT01281501
Drug: Oral antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)
Trial: NCT03156920
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
Trial: NCT02724254
Drug: AP611074 5% gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02672436
Drug: ENERGI-F703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care and ENERGI-F703 are applied for treatment of diabetic foot ulcers.
Trial: NCT02672436
Drug: ENERGI-F703 matched vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
Trial: NCT02424942
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solvent for parenteral use~Route of administration: intraarticular
Trial: NCT02424942
Drug: GZ389988
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:suspension for injection~Route of administration: intraarticular
Trial: NCT00833339
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00975299
Drug: BAY86-4367
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cancer patients, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, PET/CT
Trial: NCT00975299
Drug: BAY86-4367
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Healthy volunteers, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, whole body PET/CT for determination of effective dose., kinetics of BAY86-4367 in blood
Trial: NCT02187172
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04264130
Drug: Artemether-Lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subjects received artemether-lumefantrine according to their body weight twice per day for three days.
Trial: NCT00345839
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg QD, once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
Trial: NCT01149473
Drug: Losartan potassium/Hydrochlorothiazide
RxNorm normalized name: losartan potassium/hydrochlorothiazide 100 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100/25 mg Tablets
Trial: NCT03721744
Drug: GB201
RxNorm normalized name: ELECTRIC GREEN BARB TRANSGENIC WHOLE (GB2011 RDNA CONSTRUCT)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GB201 will be administered orally, twice daily, with doses separated by approximately 8-12 hours. GB201 administration will begin 2-5 days prior to the first infusion of paclitaxel and low-dose gemcitabine
Trial: NCT01133353
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 to 5 tablets once per day depending on weight for 12 weeks
Trial: NCT01901705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo was a mixture of blue dye powder (54.8% Indigo carmine aluminum lake \[Blue #32\] and 45.2% Allura Red AC aluminum lake \[Red #40\] powders), Vaseline, microcrystalline wax, and olive oil.
Trial: NCT02535715
Drug: ORMD-0801 capsules- 2x8mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who receive this intervention first, then receive either ORMD-0801- 3x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
Trial: NCT02535715
Drug: ORMD-0801 capsules- 3x8mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 1x16mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
Trial: NCT02535715
Drug: ORMD-0801 capsules- 1x16mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who receive this intervention first, then receive either ORMD-0801- 2x8mg or 3x8mg dose after a 3 day to 4 week interval. Participants receiving this drug as the second drug intervention will then receive the third intervention after a 3 day to 4 week interval. ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
Trial: NCT01032837
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo provided as capsules and as a suspension.
Trial: NCT00139776
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily.~Placebo used as flare medication when directed.
Trial: NCT00139776
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily.~Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed.
Trial: NCT05244759
Drug: [14C]-BLU-5937
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive a single oral administration of \[14C\]-BLU-5937 capsule, in the fasted state.
Trial: NCT00497107
Drug: UFT, Calcium Folinate, PSK
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00497107
Drug: UFT, Calcium Folinate
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04119921
Drug: prescription topical ketorolac in group 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
Trial: NCT00914927
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or inactive substance once a day for up to 7 days
Trial: NCT01472770
Drug: Gemcitabine + Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine: 1000 mg/m2 intravenously over 30 min. on day 1 in 2-weeks cycles. Capecitabine: Peroral tablet 2000 mg/m2 daily on days 1-7 in 2-weeks cycles.
Trial: NCT04347915
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo once a day for 14 days (up to 21 days)
Trial: NCT01911442
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01378039
Drug: comparison of treatment effect on different markers
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inhaled budesonide (400 µg BD) or placebo BD
Trial: NCT04119921
Drug: prescription artificial tear in group 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
Trial: NCT03423680
Drug: Abilify 2, 5, 10, 15mg (Tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
Trial: NCT04119921
Drug: prescription topical ketorolac in group 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artificial tear every 6 hour in the first interval and then topical ketorolac every 6 hour as a placebo in the second interval.
Trial: NCT01119742
Drug: Vehicle A
RxNorm normalized name: Vehicle and emulsifier patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application for 7 days
Trial: NCT01119742
Drug: Vehicle B
RxNorm normalized name: vehicle base no.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily application for 7 days
Trial: NCT04660461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects are randomized to recieve Lansoprazole 30mg/day or placebo during 8 weeks. After a washing-out period of 15 days, subjects will receive the other treatment (cross-over design) during 8 weeks
Trial: NCT03423680
Drug: Placebo of Abilify 2, 5, 10, 15mg (Tablet)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized subjects will take 1 tablet of aripiprazole or placebo orally once daily from the baseline visit (Visit 2) to Visit 8 (Week 8 visit or discontinuation visit). The initial dose of aripiprazole, the investigational product, is 2 mg once daily (irrespective of meals), which the investigators can maintain, increase or decrease within a range of 2 - 15 mg at each scheduled study visit, depending on the subject's clinical response and tolerability.
Trial: NCT03877562
Drug: CORT118335
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CORT118335 600 mg oral tablets administered as 2 X 300 mg or 6 X 100 mg tablets
Trial: NCT03877562
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching CORT118335, 2 or 6 oral tablets, depending on the CORT118335 tablet strength available
Trial: NCT04119921
Drug: prescription artificial tear in group1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical ketorolac every 6 hour in the first interval and then artificial tear every 6 hour as a placebo in the second interval.
Trial: NCT04659161
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsules twice a day (BID)
Trial: NCT02188303
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01236573
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) over 1 hr.
Trial: NCT02584439
Drug: lactose capsule (placebo)
RxNorm normalized name: lactose Oral Capsule
DrugBank: Lactose (DB04465)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
Trial: NCT04433611
Drug: 0.9 % normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intrauterine infusion of 0.9 % normal saline
Trial: NCT02758691
Drug: Intranasal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants in the devise testing portion of the study will self-administer a 20 mL dose of intranasal saline. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 mL dose of intranasal saline.
Trial: NCT02462317
Drug: Placebo toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo injection
Trial: NCT01004237
Drug: pravastatin, valsartan, pravastatin+valsartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pravastatin 40 mg, valsartan 160 mg 8 weeks of treatment
Trial: NCT02561793
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: women will receive a placebo 12 weeks before starting IVF/ICSI
Trial: NCT01659242
Drug: Methotrexate plus sulfasalazine
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))~SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.~MTX:Kept at the highest optimal dose.
Trial: NCT01835015
Drug: CLG561
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravitreal injection, Day 1
Trial: NCT00530114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
Trial: NCT02134964
Drug: OLT1177 Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLT1177 Capsules are an experimental drug.
Trial: NCT02134964
Drug: Placebo Capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.
Trial: NCT00492323
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: twice daily for 4 weeks
Trial: NCT00630279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01606540
Drug: Tablets Ibumetin and placebo
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after reposition.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after reposition. The following days placebo tablets.~Group C: Placebo tablets 1 week after reposition.
Trial: NCT01606540
Drug: Tablets Ibumetin and placebo
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after surgery.~Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after surgery. The following days placebo tablets.~Group C: Placebo tablets for 1 week after surgery.
Trial: NCT00040482
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01765114
Drug: PEG-Formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01893632
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03533972
Drug: Ashwagandha
RxNorm normalized name: Ashwagandha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ashwagandha capsules given to the subjects twice daily after meals for 1 month
Trial: NCT01536574
Drug: Requip PR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will be dispensed medication to uptitrate their REQUIP PR dose (2, 4, 6, 8mg respectively) during the first 4 weeks of treatment. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control.
Trial: NCT01605279
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo (dextrose 5% in water, D5W, as Placebo)